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ORIGINAL ARTICLE
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Abstract
Involvement of signal transducer and activator of transcription 3 (STAT3) in inflammation is
well known. Recently, a role for STAT3 in platelet activation and platelet production has been
suggested. Platelets exhibit important immune functions and engagement of STAT3 in platelet
physiology may link inflammation and hemostasis. This study investigated the effects of STAT3
loss-of-function mutations and single nucleotide polymorphisms (SNPs) in STAT3 on glycopro-
tein VI (GPVI)-mediated platelet activation and platelet numbers in humans. Two cohorts were
studied. The first cohort concerned patients with STAT3 loss-of-function mutations. Platelet
numbers were investigated in eight patients and GPVI-mediated platelet activation was func-
tionally tested in four patients. Additional experiments were performed to investigate under-
lying mechanisms. The second cohort concerned 334 healthy volunteers and investigated the
consequences of SNPs in STAT3 on GPVI-mediated platelet activation and platelet numbers.
Platelet activation was lower in STAT3 loss-of-function patients at baseline and after stimula-
tion of the GPVI receptor, reflected by decreased P-selectin expression. This was independent
of gene transcription. Blockade of the adenosine di-phosphate (ADP) pathway resulted in a
further decrease of P-selectin expression, particularly in STAT3 loss-of-function patients. In
contrast, the SNPs in STAT3 did not influence GPVI-mediated platelet activation. Also, platelet
numbers were not affected by STAT3 loss-of-function mutations, nor was there an association
with the SNPs. In conclusion, STAT3 signaling does not seem to play a major role in thrombo-
poiesis. We confirm that STAT3 is involved in GPVI-mediated platelet activation in humans,
independent of gene transcription. GPVI-mediated platelet activation is highly dependent on
secondary ADP release. Our findings suggest that STAT3 modulation may affect inflammation,
hemostasis, and their interaction.
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Introduction
28 September 2017 STAT3 was shown to play a role in platelet
activation [9–11] and in thrombopoiesis [12]. Zhou and collea-
gues reported that platelet activation via surface receptor glyco-
protein VI (GPVI) is impaired in platelet STAT3-knockout mice
[9]. Additionally, ex vivo STAT3 inhibition by pharmacological
inhibitors resulted in decreased platelet activation and less throm-
bus formation after stimulation of GPVI with platelet agonist
collagen-related peptide (CRP) in humans [9]. Grozovsky and
colleagues showed involvement of STAT3 in platelet production
[12]. Binding of desialylated platelets to the Ashwell–Morell
receptor induced hepatic thrombopoietin (TPO) via a mechanism
dependent on STAT3 in mice [12]. These studies suggest that
STAT3 may be involved in primordial platelet physiology; how-
ever, most evidence is derived from mouse models and cell lines:
further validation of its importance in humans is therefore
warranted.
This study investigated involvement of STAT3 in platelet
activation and platelet numbers in humans. Two independent
cohorts were studied. The first cohort concerned patients with
STAT3 loss-of-function mutations. STAT3 loss of function is rare
but nonetheless observed in humans and results in the hyper IgE
syndrome, an immune deficiency disorder associated with recur-
rent infections, eczema, mucocutaneous candidiasis, and extreme
elevations of serum IgE [13,14]. Patients with STAT3 loss of
function are deficient in STAT3-dependent cytokines, such as
interleukin (IL)-17. It is unknown whether thrombopoiesis and
platelet function are affected in humans with mutations in STAT3.
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The second cohort concerned healthy human volunteers and
investigated the effects of single nucleotide polymorphisms
(SNPs) in STAT3 on platelet activation and platelet numbers.
These data are important to understand its function on a popula-
tion level. We demonstrate that both mutations and SNPs in
STAT3 do not influence platelet numbers in humans, whereas
STAT3 loss-of-function mutations do affect GPVI-mediated pla-
telet activation by CRP. Additionally, we observed that GPVI-
mediated platelet activation was largely dependent on secondary
stimulation by adenosine di-phosphate (ADP), thereby partially
restoring the defect observed in STAT3 loss-of-function patients.
Methods
Patients selection
Cohort 1. Subjects with STAT3 loss-of-function mutations
Autosomal-dominant cases of hyper IgE syndrome (AD-HIES)
are caused by specific mutations that result in nonfunctional
STAT3 activity [15]. Most mutations are found at positions that
are well known for STAT3 function, such as the Src homology
(SH2) domain that enables recruitment and binding of STAT3
to the activated receptor and the DNA-binding domain that
enables binding of STAT3 to DNA target sites [14]. The vast
majority of AD-HIES cases are due to these heterozygous
mutations resulting in absent STAT3 activity; however, several
other mutations have been described [13,16]. To examine the
effects of STAT3 loss-of-function mutations on platelet num-
bers, medical records of eight confirmed heterozygous AD-
HIES patients were consulted. Additionally, we were able to
functionally assess GPVI-mediated platelet activation in 4 of
these patients and in 10 control subjects. IL-17 production has
been previously tested in peripheral blood mononuclear cells of
these patients and the IL-17 deficiency served as a further
confirmation of the STAT3 loss of function [17]. Control sub-
jects were healthy individuals who were age and gender
matched with AD-HIES patients. No genotyping for specific
STAT3 mutations was performed in control subjects because
the incidence is exceptionally low and severe medical com-
plaints manifest early in life. The control subjects did not
experience any medical complaints during recruitment.
Subjects were recruited under a protocol approved by the
Institutional Review Board of Radboud University Nijmegen
Medical Center. AD-HIES patients are referred to as STAT3
loss-of-function patients.
Cohort 2. STAT3-related SNPs in healthy subjects
Several SNPs in STAT3 that are associated with inflammatory
diseases were identified from literature [18–20]. In contrast to the
STAT3 loss-of-function mutations, the SNPs in STAT3 are asso-
ciated with inflammatory diseases that are accompanied by
increased IL-17 levels. Differentiation of Th-17 cells is dependent
on STAT3, which suggests increased STAT3 activity [20]. We
determined these SNPs using DNA from the 500 functional
genomics cohort and correlated these with GPVI-mediated plate-
let activation and platelet numbers. This cohort consists of 534
healthy individuals of Caucasian origin and is part of the Human
Functional Genomics Project aimed at characterizing variations in
immune function [21,22]. More detailed information on the study
design and the characteristics of study participants can be found
in previous publications [22,23]. Individuals were recruited under
a protocol approved by the Institutional Review Board of
Radboud University Nijmegen Medical Center.
Experiments cohort 1
Platelet activation and responsiveness assay
Blood from STAT3 loss-of-function patients during stable disease
and healthy subjects was collected in 3.2% sodium citrate vacu-
tainer tubes (Becton Dickinson, Franklin Lakes, New Jersey,
USA). Whole blood was centrifugated for 15 min at 156g without
break to obtain platelet-rich plasma (PRP). Platelet concentration
was adjusted to 300 × 109/l by addition of autologous platelet-
poor plasma (PPP). PPP was obtained after centrifugation of
whole blood at 3800 RPM for 10 min. PRP was rested for 1 h
before platelet functions were assessed.
Platelet expression of activation marker P-selectin was mea-
sured in PRP at baseline and after incubation for 20 min with
different concentrations of platelet agonist cross-linked CRP
(kind gift from Prof. Dr. R. Farndale, Cambridge, UK) to
stimulate the GPVI surface receptor. Thrombin receptor-activat-
ing peptide-6 (TRAP) (Sigma-Aldrich, Saint Louis, Missouri,
USA), an agonist for the thrombin receptor proteinase-activated
receptor-1, served as a positive control. Samples were incubated
with nine concentrations of CRP (range 1.3–320 ng/ml) and
two concentrations of TRAP (9.78 and 156 µm) together with
antibodies for flow cytometry. The reaction was stopped by
addition of 0.2% paraformaldehyde. P-selectin expression was
measured with a Becton Dickinson flow cytometer. In order to
identify platelets, platelets were gated based on forward and
sideward scatter and additional gating was performed based on
expression of platelet surface marker CD61 (PC7 labeled anti-
CD61, Beckman Coulter, Brea, California, USA). To determine
platelet activation, the mean fluorescence intensity (MFI)
exceeding that of the matched isotype of P-selectin (PE labeled
anti-CD62P, Bio-legend, San Diego, California, USA) was
determined.
Inhibition of ADP pathway with apyrase
Activation via the GPVI surface receptor results in platelet degra-
nulation of dense granules thereby releasing biologically active
substances, most notably ADP. ADP can activate platelets via a
secondary pathway. In order to avoid skewing of the responses by
platelet activation via this positive feedback loop, additional experi-
ments were performed after preincubation with apyrase, to block the
ADP pathway. Apyrase was purchased from Sigma-Aldrich (Saint
Louis, Missouri, USA). For experiments, a final concentration 5 U/
ml was used. After incubation with apyrase, PRP samples were
stimulated with CRP at concentrations 320, 80, and 20 ng/ml in
combination with the antibodies for flow cytometry. The same
protocol and gating strategies as described above were used.
Inhibition of transcription during platelet activation
STAT3, as a transcription factor, regulates DNA transcription and
exerts its effects after phosphorylation, dimerization, and translo-
cation to the nucleus [24]. Platelets do not have a nucleus and
exclusively contain mitochondrial DNA. Experiments with tran-
scription blocker actinomycin were performed to investigate the
role of DNA transcription in this process. Actinomycin was
purchased from Sigma-Aldrich (Saint Louis, Missouri, USA)
and dissolved in DMSO, stock concentration 6270 µg/ml. PRP
was preincubated with actinomycin D in two concentrations (50
and 5 µg) and DMSO control, before samples were stimulated
with CRP. The CRP concentration of 40 ng/ml was chosen as it
was estimated that platelet responses would be in the steep part of
the platelet reactivity curve. The same protocol for stimulation
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and similar gating strategies as described above was used for
measurement of P-selectin expression.
Platelet content and plasma markers
Soluble plasma markers and platelet content of P-selectin, fibri-
nogen were determined by ELISA. For platelet content, PRP
(concentration 300 × 109 platelets/ml) was freeze thawed for
three cycles to fragment the platelets. Samples were centrifugated
at room temperature for 5 min at 5000 RPM in an ultracentrifuge
to spin down large particles. Supernatants were used for ELISA.
PPP was used for plasma markers. Soluble P-selectin and soluble
fibrinogen were measured using a human P-selectin/CD62P duo-
set ELISA kit (R&D systems, Europe, Abingdon, UK) and a
human fibrinogen ELISA kit (Abcam, Europe, Cambridge, UK),
respectively. TPO was measured with a human TPO Quantikine
ELISA kit (R&D systems, Europe, Abingdon, UK).
Experiments cohort 2
SNPs in STAT3
Genotyping of the SNPs was performed using a commercially
available SNP chip, Illumina HumanOmniExpressExome-8 v.1.0,
methods previously reported by Li et al. [23]. In short, genotype
calling was performed using Optical 0.7.0 [25]. Call rates less
than ≤0.99 were excluded from the dataset, as were samples with
a Hardy–Weinburg equilibrium ≤0.0001, call rate ≤0.99, and
minor allele frequencies (MAF) ≤0.001. In total, 483 samples
were included for further imputation, as described previously.
Data were extracted for the following SNPs: rs744166,
rs3816769, and rs4796793. Presence of the SNP was related to
platelet activation in response to CRP and to platelet numbers.
Platelet activation and responsiveness assay
For assessment of platelet activation and responsiveness, platelet
P-selectin expression was measured in whole blood at baseline
and after incubation for 20 min with seven different concentra-
tions of platelet agonists CRP, together with an antibody mix for
flow cytometry. The same protocol and gating strategies as
described above were used for measurement of P-selectin expres-
sion. The area under the curve (AUC) of the P-selectin expression
after stimulation (MFI) was correlated with the SNP data. In total,
data were available for 334 healthy human volunteers.
Statistical analysis
Cohort 1. Quantitative data are expressed as median with inter-
quartile range (IQR) and were analyzed with GraphPad Prism 5.
Repeated measures like platelet responsiveness upon stimulation
were analyzed using a two-way ANOVA in order to correct for
the multiple independent observations. To compare singular mea-
surements between groups Mann–Whitney U tests were per-
formed for non-normally distributed data.
Cohort 2. Platelet numbers were normally distributed, in
contrast to P-selectin expression. To normalize P-selectin
expression (AUC), data were log transformed. Formal correc-
tion for age and gender effects in both outcome parameters was
performed. SNP genotypes were coded 0, 1, and 2, before
linear regression analyses were performed with SPSS with
use of dummy variables.
p Values < 0.05 were considered statistically significant.
Results
Characteristics of study participants
Main characteristics of the two study cohorts are presented in
Table I. The first cohort concerned eight STAT3 loss-of-function
patients, five patients had a mutation in the DNA-binding domain,
two in the SH2-domain, and one patient had a mutation in the
Linker domain of STAT3. The second cohort involved 483
healthy human volunteers of which 334 participants data on
SNPs and GPVI-mediated platelet activation were available. A
more detailed description of the specific mutations in the STAT3
loss-of-function patients can be found in Table II.
Less platelet activation and GPVI-mediated platelet
responsiveness in STAT3 loss-of-function patients
To investigate the involvement of STAT3 in platelet activation, we
determined baseline platelet activation in STAT3 loss-of-function
patients. Platelet activation, determined by P-selectin expression,
was significantly lower in STAT3 loss-of-function patients com-
pared to control subjects (median MFI 3.03 [IQR 2.62–3.84] vs.
4.82 [IQR 3.53–5.67], p = 0.01) (Figure 1A). Next, we investi-
gated whether collagen-induced platelet activation by stimulation
of GPVI surface receptor with CRP was affected. Stimulation of
the GPVI receptor with different concentrations of CRP (range
1.3–320 ng/ml) resulted in significantly lower P-selectin expres-
sion in STAT3 loss-of-function patients compared to control sub-
jects (p < 0.001) (Figure 1B). To examine whether this
observation was due to an intrinsic platelet defect or whether it
resulted from the theoretical possibility of defective production of
factors that prime platelets, platelets were stimulated with another
agonist, TRAP, as a control. Although platelet responses were
slightly lower with TRAP (Figure 1C), this effect was not statis-
tically significant after correction for lower baseline P-selectin
expression, suggesting a largely intrinsic defect in platelets.
Table I. Patient characteristics.
Cohorts STAT3 loss-of-function cohort SNP cohort
AD-HIES Control
subjects
Healthy
individuals
Number (n) 8 10 483
Age (mean, SD) 38 ± 10.5 32 ± 9.2 28.5 ± 13.7
Gender (% male) 37.5 40 44.3
Mutation domain
(n)
N/A N/A
DNA-binding
domain
5
SH2 domain 2
Linker-domain 1
SNP frequency* N/A N/A
rs744166 31.5/48.4/20.1%
rs3816769 58.6/37.0/4.4%
rs4796793 37.7/48.9/13.4%
Medication Antifungal therapy,
prophylactic
antibiotic treatment
No
medication
No medication
Clinical
complications
Recurrent RTIs,
eczema, “cold
abscesses”
None None
Characteristics of the two study cohorts. AD-HIES: Autosomal-dominant
hyper IgE syndrome; N/A: not applicable; RTI: respiratory tract infection;
SH2: Src Homology 2; SNP: single nucleotide polymorphism.
*Homozygous for common allele/heterozygous/homozygous for rare allele.
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Inhibition of the ADP pathway further attenuates platelet
responsiveness in STAT3 loss-of-function patients
GPVI-mediated platelet activation results in platelet degranula-
tion, thereby releasing biologically active substances, in particular
ADP from dense granules [26]. In order to investigate depen-
dency of the GPVI-mediated platelet activation pathway on sec-
ondary ADP release, we incubated samples with apyrase to block
this pathway. Stimulation of the GPVI receptor by different con-
centrations of CRP after incubation of samples with apyrase
resulted in considerably lower P-selectin expression in both
groups. Inhibition of the ADP pathway seems to have a more
profound effect in STAT3 loss-of-function patients than in healthy
subjects, as the relative increase from baseline to the highest CRP
concentration was 5.7-fold in STAT3 loss-of-function patients
compared to 11.4-fold in control subjects (Figure 1D).
STAT3 signaling in GPVI-mediated platelet activation is
independent of gene transcription
Platelets do not have a DNA-containing nucleus; however, plate-
lets do possess functional mitochondrial DNA [26]. In order to
exclude the theoretical possibility of involvement of novel DNA
transcription in platelet activation in response to CRP stimulation,
transcription was inhibited by general transcription blocker acti-
nomycin D. After incubation of PRP samples with actinomycin
D, samples were stimulated with CRP. No changes in expression
of P-selectin were seen after inhibition of transcription in both
patients and control subjects (data not shown).
No differences in platelet content and soluble markers were
found in STAT3 loss-of-function patients
Previous experiments suggest an intrinsic platelet defect in patients
with STAT3 loss-of-function mutations. In addition, inhibition of
the ADP pathway had a relatively higher impact on GPVI-mediated
platelet activation in STAT3 loss-of-function patients. To examine
whether these observations were a result of alterations in granule
content, we measured P-selectin and fibrinogen in platelet lysates.
No differences were seen in platelet content for P-selectin and
fibrinogen (327.0 ng/ml [IQR 153.9–523.5] in patients vs.
261.1 ng/ml [IQR 204.3–325.5] in control subjects, p-value 0.84
and 2420 µg/ml [IQR 1786–3813] in patients, and 2092 µg/ml
[IQR 1038–2938] in control subjects, p-value 0.52, respectively).
This suggests that previous observations are more likely due to
lower platelet granule release in response to stimulation than
alterations in granule content.
Lastly, P-selectin and fibrinogen in plasma was determined as
a measure for platelet granules release. Interestingly, no signifi-
cant differences were found in soluble plasma P-selectin and
fibrinogen between patients and control subjects (median
41.7 ng/ml [IQR 27.0–47.3] vs. 27.9 ng/ml [21.9–44.2], p-value
Table II. STAT3 loss-of-function mutations.
Protein domain
Site of
mutation
DNA sequence
change
Predicted
amino acid
change
Number
of
patients
DNA-binding Exon 13 1144C → T R382W 2* (1)
Exon 13 1145G → A R382Q 1
Exon 16 1387 deletion
GTG
V463
deletion
1
Intron
11
1110-2A → G G380
deletion
1*
SH2 Exon 21 1909C → G V637L 1
Exon 21 1909G → A V637M 1*
Linker domain Exon 19 1679-1681
deletion
S560
deletion
1*
Specification of the STAT3 loss-of-function mutations.
DNA: Deoxyribonucleid acid; SH2: Src Homology 2. Patients indicated
with an asterisk (*) were functionally assessed. (1): one of the 2 patients
was functionally assessed.
Figure 1. Functional assessment of GPVI-mediated platelet activation in STAT3 loss-of-function patients.(A) Platelet P-selectin expression in
unstimulated samples (median MFI 3.03 (IQR 2.62–3.84) in STAT3 loss-of-function versus 4.82 (IQR 3.53–5.67) in control subjects, p = 0.01).
(B) Platelet P-selectin expression in GPVI-mediated platelet activation by CRP stimulation (p < 0.001). (C) Platelet P-selectin expression in PAR-1-
mediated platelet activation by TRAP (p = 0.054). (D) P-selectin expression in GPVI-mediated platelet activation by CRP after blockade of the ADP
pathway by apyrase. Data are presented as median with IQR (ADP: adenosine 5′ diphosphate; CRP: collagen-related peptide; GPVI: glycoprotein VI;
MFI: mean fluorescence intensity; TRAP: thrombin receptor-activating peptide-6).
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0.45 and mean 2513 µg/ml [IQR 1826–3016] vs. 2640 µg/ml
[IQR 2240–3114], p-value 0.74, respectively).
SNPs in STAT3 do not correlate with GPVI-mediated platelet
activation in healthy volunteers
To investigate the involvement of STAT3 on platelet activation on a
population level, several SNPs in STAT3 that are associated with
inflammatory diseases were investigated. The three SNPs, rs744166,
rs3816769, and rs4796793, were determined in the second cohort,
concerning healthy volunteers. These SNPs are known from litera-
ture to be functional and are likely to influence STAT3 activity in
relation to several diseases, such as Crohn’s disease, ulcerative
colitis, and autoimmune thyroid disease [18–20]. The MAF of
rs744166, rs3816769, and rs4796793 were C = 0.439/964,
C = 0.254/964, and C = 0.378/964, respectively. The MAFs were
similar to the MAFs reported in the NCBI database (http://www.
ncbi.nlm.nih.gov/SNP), except for rs3816769 with a MAF of
C = 382/1912 in the NCBI database.
Linear regression analysis was performed for SNP genotype
and platelet activation in response to GPVI stimulation (AUC).
No significant correlations could be detected for rs744166,
rs3816769, and rs4796793 with GPVI-mediated platelet activa-
tion (p > 0.05). The SNP characteristics and the relation between
the SNPs and GPVI-mediated platelet activation are shown in
Figure 2. In contrast to previous observations, SNPs in STAT3 do
not seem to affect GPVI-mediated platelet activation.
Platelet numbers are not influenced by STAT3 mutations
and STAT3 SNPs
Lastly, we studied platelet production. Platelet production is pri-
marily regulated by TPO concentrations in blood and it has
recently been suggested that hepatic TPO production is dependent
on signaling via STAT3 [12]. Platelet numbers retrieved from
medical records of eight confirmed STAT3 loss-of-function
patients were mostly within the normal range (Table III).
Interestingly, thrombocytosis was observed in two patients during
an acute infection. Thrombocytopenia was not observed in STAT3
loss-of-function patients. In addition, plasma TPO levels were
determined in the 4 functionally assessed STAT3 loss-of-function
patients and the 10 healthy subjects. Although most values were
below the detection limit of 15.6 pg/ml, two STAT3 loss-of-
function patients had detectable TPO levels (24.0 and 79.7 pg/
ml) (Figure 3A). Several studies suggest that IL-6 stimulates
thrombopoiesis [27,28]. Therefore, we determined IL-6 levels in
plasma. A trend for higher IL-6 was observed in STAT3 loss-of-
function patients (Figure 3B).
Also the effects of the SNPs in STAT3 were examined.
Consistently with the observation in the STAT3 loss-of-function
patients, no significant influence of the SNPs on platelet numbers
was observed in 334 healthy subjects (Table III). Importantly,
both thrombocytopenia and thrombocytosis were rarely observed.
Discussion
The present study investigated the involvement of STAT3 in
GPVI-mediated platelet activation and platelet numbers in
humans. Our findings indicate that GPVI-mediated platelet acti-
vation is affected by STAT3 loss-of-function mutations confirm-
ing its involvement in platelet function in humans. In contrast,
neither clinically relevant STAT3 loss-of-function mutations nor
SNPs in STAT3 affected platelet numbers in humans.
Further experiments were performed to increase our understand-
ing of its function. GPVI-mediated platelet activation was shown to
be largely dependent on secondary stimulation by platelet ADP
release, both in patients and in healthy subjects. Blockade of this
mechanism strongly attenuated platelet responses, particularly in
STAT3 loss-of-function patients. These observations were indepen-
dent of gene transcription, as previously reported [9]. Although
STAT3 is commonly known as a transcription factor, its involvement
in platelet activation appears to be non-transcriptional and few non-
transcriptional properties of STAT3 have been previously described
[29,30]. SNPs in STAT3 did not directly affect GPVI-mediated
platelet activation in a healthy population. In some inflammatory
diseases, the effects of SNPs in STAT3 on platelet activation may
become apparent; however, in healthy individuals, robust mechan-
isms seem to balance inflammation and hemostasis.
Interestingly, P-selectin levels in plasma were not different
between STAT3 loss-of-function patients and control subjects,
whereas platelet degranulation was decreased in patients.
Another source for soluble P-selectin is the vascular endothelium
[31]. Both vascular abnormalities and endothelial dysfunction are
common in hyper IgE syndrome and may explain this observa-
tion [32].
With the lack of an effect on platelet numbers, we report an
opposite effect compared to a previous study that suggests an impor-
tant role for STAT3 in the hepatocytic production of TPO, the most
important regulator of platelet formation by megakaryocytes [12]. In
addition to a mouse model, it was shown that desialylated platelets
are taken up by a human HepG2 cells and these cells subsequently
Figure 2. SNPs rs744166, rs3816769, and rs4796793 and P-selectin expression (AUC).SNP characteristics are shown in the upper figure. P-selectin
expression (AUC of MFI) after GPVI-mediated platelet activation by seven concentrations of CRP is shown in the lower figure. Data are presented as
median with IQR (AUC: Area under the curve; CRP: collagen-related peptide, GPVI: glycoprotein VI; IQR: interquartile range; MAF: minor allele
frequency; MFI: mean fluorescence intensity; SNP: single nucleotide polymorphism).
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produce TPO in a Janus kinase-2 (JAK2)/STAT3-dependent manner
[12]. In contrast, we did not find a decrease in platelet numbers in
patients with defective STAT3 signaling; moreover, thrombocytosis
was observed in STAT3 loss-of-function patients during acute infec-
tions. TPO levels were detectable in plasma in two patients, whereas
these were low or undetectable in control subjects. A direct compar-
ison between groups is limited by the fact that TPOwas undetectable
in most subjects and these results should be interpreted with caution.
A trend was seen for increased IL-6 in patients and this may also
stimulate thrombopoiesis [27,28]. Our findings suggest that in vivo
other mechanisms also regulate platelet production in humans.
The observation that STAT3 is involved in GPVI-mediated
platelet activation further validates that the mechanism reported
by Zhou and colleagues may be functional and relevant in humans
too [9]. Involvement of STAT3 in platelet activation may provide
a relevant link between inflammation and hemostasis. Increased
activation of the STAT3 signaling pathway has been described in
cancer and many inflammatory diseases, including cardiovascular
diseases [4–8,33]. Cardiovascular disease is the leading cause of
death worldwide and interestingly, risk for cardiovascular diseases
is strongly increased in many inflammatory diseases [34]. To
examine whether GPVI-mediated platelet activation was affected
by SNPs in STAT3, we studied a cohort of healthy human
volunteers; however, no relation was observed. The role of
STAT3 activation in inflammatory diseases and its consequences
for platelet activation needs further exploration. Especially since
it is unknown if the SNPs in STAT3 affect STAT3 function in
healthy subjects, or whether aberrant STAT3 function becomes
apparent in inflammatory diseases.
Blockade of STAT3 is currently being explored as a new
therapy for cancer [35,36]. Several STAT3 inhibitors have
recently proceeded into clinical trials and also drugs that block
JAK2, such as Ruxolitinib [35,37,38]. It is important that involve-
ment of STAT3 in platelet activation is recognized. Bleeding
complications may occur, especially in patients who are concur-
rently treated with platelet inhibitors that target other pathways
such as Ticagrelor and Clopidogrel, targets of the ADP receptor,
P2Y12. GPVI-mediated platelet activation is highly dependent on
secondary activation via ADP and suppression of both pathways
may have important consequences in terms of bleeding [39–41].
The relevance of the functional impairment in patients with
AD-HIES seems to be limited due to the positive feedback loop
by ADP, which partially restores platelet responses. Although
severe bleeding complications are reported, they mostly coincide
with opportunistic infections in AD-HIES patients who often have
bronchiectasis, both features known to provoke pulmonary
hemorrhages [42,43]. Interestingly, in one AD-HIES patient, a
spontaneous bleeding was recorded that could not be explained
from a clinical perspective. The bleeding occurred in the iliopsoas
muscle and was not preceded by any kind of trauma. Examination
of the medical history of the other patients did not reveal any
unexplained spontaneous bleedings.
Our study has a few limitations. The first limitation is that we
were unable to relate platelet responses directly to STAT3 func-
tion and different STAT3 isoforms. STAT3 has several isoforms
that mostly result from alternative mRNA splicing. These iso-
forms can have distinct functions; STAT3β, for example, lacks the
Ser727 phosporylation site and is thought to be a negative reg-
ulator [44]. The exact mechanisms by which STAT3 mutations
cause STAT3 loss-of-function are still largely unknown [14]. It
would have been of great interest to directly relate STAT3 iso-
forms and STAT3 activity to GPVI-mediated platelet responses.
Also the question whether there is a compensatory increase in
other STATs needs further investigation, as STATs can both form
homodimers and heterodimers with different functions [44]. The
second limitation is the limited sample size of STAT3 loss-of-
function patients (AD-HIES patients). This makes our findings
less robust. AD-HIES is a very rare disease with an estimated
prevalence of 1:100 000 [14,45]. It has to be noted that the effects
observed were consistent in patients and in different
Table III. Median platelet numbers (range).
STAT3 loss-of-function
cohort
Highest
(platelets × 109/l)
Lowest
(platelets × 109/l)
♀, 46 years 264 229
♀, 46 years* 247 160
♀, 23 years* 505 231
♂, 47 years* 317 168
♂, 26 years 242 133
♀, 34 years 314 205
♀, 32 years* 431 175
♀, 50 years 257 206
SNP cohort Wild type Heterozygous Homozygous for SNP
rs744166 274 (132–470) 257 (132–491) 268 (133–488)
rs3816769 276 (132–470) 263 (132–491) 266 (133–488)
rs4796793 280 (159–401) 275 (132–491) 261 (132–488)
Platelet numbers from STAT3 loss-of-function patients, platelets × 109/l,
and platelet numbers from the SNP cohort, median platelet
numbers × 109/l (range). Patients indicated with an asterisk (*) were
functionally assessed. ♀: Female; ♂: male; SNP: single nucleotide
polymorphism.
Figure 3. TPO and IL-6 levels in plasma.(A) Plasma TPO levels in STAT3 loss-of-function patients and control subjects. (B) Plasma IL-6 expression in
STAT3 loss-of-function patients and control subjects (IL-6: Interleukin-6; TPO: thrombopoietin).
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concentrations of CRP. Lastly, STAT3 loss-of-function patients
are treated with prophylactic antimicrobial therapy and we were
unable to correct for those differences in the healthy subjects.
Therefore, we cannot completely exclude a potential effect of
medication on our findings.
In conclusion, our findings indicate that STAT3 is involved in
GPVI-mediated platelet activation by CRP in humans.
Additionally, GPVI-mediated platelet activation was shown to
be largely dependent on secondary stimulation by ADP. In con-
trast, neither clinically relevant STAT3 loss-of-function mutations
nor SNPs affecting STAT3 activity influence platelet numbers in
humans. These data improve our understanding on the interaction
between inflammation and hemostasis and suggest that STAT3
modulation may affect both inflammation and hemostasis and
their interaction in humans.
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